315 related articles for article (PubMed ID: 29679469)
1. Influence of Transporter Polymorphisms on Drug Disposition and Response: A Perspective From the International Transporter Consortium.
Yee SW; Brackman DJ; Ennis EA; Sugiyama Y; Kamdem LK; Blanchard R; Galetin A; Zhang L; Giacomini KM
Clin Pharmacol Ther; 2018 Nov; 104(5):803-817. PubMed ID: 29679469
[TBL] [Abstract][Full Text] [Related]
2. The role of transporters in toxicity and disease.
Schuetz JD; Swaan PW; Tweedie DJ
Drug Metab Dispos; 2014 Apr; 42(4):541-5. PubMed ID: 24598705
[TBL] [Abstract][Full Text] [Related]
3. Human membrane transporter database: a Web-accessible relational database for drug transport studies and pharmacogenomics.
Yan Q; Sadée W
AAPS PharmSci; 2000; 2(3):E20. PubMed ID: 11741236
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics and the treatment of functional gastrointestinal disorders.
Halawi H; Camilleri M
Pharmacogenomics; 2017 Jul; 18(11):1085-1094. PubMed ID: 28686075
[TBL] [Abstract][Full Text] [Related]
5. Effects of drug transporters on volume of distribution.
Grover A; Benet LZ
AAPS J; 2009 Jun; 11(2):250-61. PubMed ID: 19399628
[TBL] [Abstract][Full Text] [Related]
6. Membrane transporters in drug development and as determinants of precision medicine.
Galetin A; Brouwer KLR; Tweedie D; Yoshida K; Sjöstedt N; Aleksunes L; Chu X; Evers R; Hafey MJ; Lai Y; Matsson P; Riselli A; Shen H; Sparreboom A; Varma MVS; Yang J; Yang X; Yee SW; Zamek-Gliszczynski MJ; Zhang L; Giacomini KM
Nat Rev Drug Discov; 2024 Apr; 23(4):255-280. PubMed ID: 38267543
[TBL] [Abstract][Full Text] [Related]
7. Identifying genomic and developmental causes of adverse drug reactions in children.
Becker ML; Leeder JS
Pharmacogenomics; 2010 Nov; 11(11):1591-602. PubMed ID: 21121777
[TBL] [Abstract][Full Text] [Related]
8. Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.
Zamek-Gliszczynski MJ; Taub ME; Chothe PP; Chu X; Giacomini KM; Kim RB; Ray AS; Stocker SL; Unadkat JD; Wittwer MB; Xia C; Yee SW; Zhang L; Zhang Y;
Clin Pharmacol Ther; 2018 Nov; 104(5):890-899. PubMed ID: 30091177
[TBL] [Abstract][Full Text] [Related]
9. The International Transporter Consortium: Summarizing Advances in the Role of Transporters in Drug Development.
Giacomini KM; Galetin A; Huang SM
Clin Pharmacol Ther; 2018 Nov; 104(5):766-771. PubMed ID: 30137696
[No Abstract] [Full Text] [Related]
10. Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.
Evers R; Piquette-Miller M; Polli JW; Russel FGM; Sprowl JA; Tohyama K; Ware JA; de Wildt SN; Xie W; Brouwer KLR;
Clin Pharmacol Ther; 2018 Nov; 104(5):900-915. PubMed ID: 29756222
[TBL] [Abstract][Full Text] [Related]
11. Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drug-Drug Interaction Evaluation: Perspectives From the International Transporter Consortium.
Chu X; Liao M; Shen H; Yoshida K; Zur AA; Arya V; Galetin A; Giacomini KM; Hanna I; Kusuhara H; Lai Y; Rodrigues D; Sugiyama Y; Zamek-Gliszczynski MJ; Zhang L;
Clin Pharmacol Ther; 2018 Nov; 104(5):836-864. PubMed ID: 30347454
[TBL] [Abstract][Full Text] [Related]
12. Irinotecan Alters the Disposition of Morphine Via Inhibition of Organic Cation Transporter 1 (OCT1) and 2 (OCT2).
Zhu P; Ye Z; Guo D; Xiong Z; Huang S; Guo J; Zhang W; Polli JE; Zhou H; Li Q; Shu Y
Pharm Res; 2018 Oct; 35(12):243. PubMed ID: 30361780
[TBL] [Abstract][Full Text] [Related]
13. Dabigatran Etexilate and Digoxin: Comparison as Clinical Probe Substrates for Evaluation of P-gp Inhibition.
Chu X; Galetin A; Zamek-Gliszczynski MJ; Zhang L; Tweedie DJ;
Clin Pharmacol Ther; 2018 Nov; 104(5):788-792. PubMed ID: 30238965
[No Abstract] [Full Text] [Related]
14. Effects of Dendrimer-Like Biopolymers on Physical Stability of Amorphous Solid Dispersions and Drug Permeability Across Caco-2 Cell Monolayers.
Lavan M; Knipp G
AAPS PharmSciTech; 2018 Aug; 19(6):2459-2471. PubMed ID: 29869315
[TBL] [Abstract][Full Text] [Related]
15. Interaction of calf brain tubulin with glycerol.
Na GC; Timasheff SN
J Mol Biol; 1981 Sep; 151(1):165-78. PubMed ID: 7328652
[No Abstract] [Full Text] [Related]
16. Can Bile Salt Export Pump Inhibition Testing in Drug Discovery and Development Reduce Liver Injury Risk? An International Transporter Consortium Perspective.
Kenna JG; Taskar KS; Battista C; Bourdet DL; Brouwer KLR; Brouwer KR; Dai D; Funk C; Hafey MJ; Lai Y; Maher J; Pak YA; Pedersen JM; Polli JW; Rodrigues AD; Watkins PB; Yang K; Yucha RW;
Clin Pharmacol Ther; 2018 Nov; 104(5):916-932. PubMed ID: 30137645
[TBL] [Abstract][Full Text] [Related]
17. Molecular Modeling of Drug-Transporter Interactions-An International Transporter Consortium Perspective.
Schlessinger A; Welch MA; van Vlijmen H; Korzekwa K; Swaan PW; Matsson P
Clin Pharmacol Ther; 2018 Nov; 104(5):818-835. PubMed ID: 29981151
[TBL] [Abstract][Full Text] [Related]
18. Roles of Renal Drug Transporter in Drug Disposition and Renal Toxicity.
Yang X; Han L
Adv Exp Med Biol; 2019; 1141():341-360. PubMed ID: 31571169
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms and Clinical Significance of Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration in 2017.
Yu J; Petrie ID; Levy RH; Ragueneau-Majlessi I
Drug Metab Dispos; 2019 Feb; 47(2):135-144. PubMed ID: 30442649
[TBL] [Abstract][Full Text] [Related]
20. 2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists.
Sudsakorn S; Bahadduri P; Fretland J; Lu C
Curr Drug Metab; 2020; 21(6):403-426. PubMed ID: 32562522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
